Small-cap stocks largely slung under the major indices Wednesday, and one of the worst-performing names was XTL Biopharmaceuticals ( XTLB).

The Valley Cottage, N.Y., firm plunged 17.2% to $2.92 on news it had suspended development on its XTL-2125 compound, a proposed treatment for hepatitis C, after an early-phase study yielded statistically insignificant results in drug efficacy.

Angeion ( ANGN), which makes noninvasive cardio-respiratory diagnostic systems, forecast reduced profitability for the fiscal third and fourth quarters vs. last year due to dwindling revenue from its largest clinical-research customer. Despite positive results for the most recent quarter, shares of the St. Paul, Minn., company lost 13.1%, or $1.42, to $9.42.

Meanwhile Georgia-based Matria Healthcare ( MATR) said it will end its short-lived relationship with insurer Wellmark Blue Cross & Blue Shield at year-end. The collaboration, which began in only February, had been originally slated to last for 10 years. Shares slid 6.3% to $29.42.

Matria helped take down with it both the Russell 2000 and the S&P SmallCap 600, which respectively gave up 0.9% and 1.1%.

Apparel maker Oxford Industries ( OXM), also a member of both indices, sank 3.5% to $42.66 after cutting its outlook for the fiscal fourth quarter and full year. Adjusted earnings for the quarter, now predicted at 96 cents to $1.01 a share, would miss Thomson Financial's estimates by at least 2 cents. Prior guidance had called for $1 to $1.07 a share.

On the flip side, Inovio Biomedical ( INO) recouped some of Tuesday's losses on word of positive preclinical results for DNA vaccines using its electroporation technology. San Diego-based Inovio, along with Wyeth ( WYE) and other partners, found the technology improved immune responses against malaria, HIV and hepatitis C vs. traditional vaccine-delivery methods. Shares surged 17.3% to $2.58, a move that partially recouped losses from disappointing news out of a separate late-phase study yesterday. Wyeth recently edged down to $57.46.

Also on the winning side today was Starent Networks ( STAR), which jumped 17.3% following its initial public offering. The Tewksbury, Mass., purveyor of wireless-communications products priced some 10.5 million shares at $12 apiece, along with a 30-day underwriters' option for another 1.6 million shares to cover any overallotments.

Elsewhere, Ivanhoe Energy ( IVAN) leapt 11.4% to $2.05 in very active trading after the Canada-based company finished testing on its heavy-oil-upgrading technology, having successfully demonstrated a "recycle" configuration that produces a "high quality" product with further reduction of viscosity. Ivanhoe expects to find a big market for this configuration in western Canada's Athabasca oilsands. The company also says it's now positioned to build full-scale commercial HTL facilities.

Finally, New Jersey-based Russ Berrie ( RUS), which makes baby and gift products, climbed 5.4% to $18.67 after rejecting an $18-per-share takeout bid by an unnamed entity. The company may still sell itself or a division, however, and says it has already received some interest after preliminarily trotting out its gift segment.

More from Investing

Why HP Enterprise's Stock Plunged After It Beat Earnings

Why HP Enterprise's Stock Plunged After It Beat Earnings

Has Wall Street Completely Lost Its Mind on General Electric?

Has Wall Street Completely Lost Its Mind on General Electric?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Did Trump Just Torpedo the Stock Market Again?

Did Trump Just Torpedo the Stock Market Again?

Venture Capital Funding Surges 49% as Tech Innovation Piques Investor Interest

Venture Capital Funding Surges 49% as Tech Innovation Piques Investor Interest